Thomas J. Moore - Dissemin

All papers authored by Thomas J. Moore

This paper was not found in any repository, but could be made available legally by the author.

2022 Thomas J. Moore

, Abdallah Alami, G. Caleb Alexander, Donald R. Mattison

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review

Upload

Distributing this paper is prohibited by the publisher

2021 Jeromie Ballreich, Charles Bennet, Thomas J. Moore

, G. Caleb Alexander

Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication

Upload

Y. Joseph Hwang, G. Caleb Alexander, Huijun An, Thomas J. Moore

, Hemalkumar B. Mehta

Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease

Upload

This paper is made freely available by the publisher.

Thomas J. Moore

, Phillip W. Wirtz, Stefan P. Kruszewski, G. Caleb Alexander

Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study

Download from doi.org

2020 Thomas J. Moore

, Morgane C. Mouslim, Jenna L. Blunt, G. Caleb Alexander, Kenneth M. Shermock

Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products

Upload

James Heyward

, Thomas J. Moore

, Jennifer Chen, Kristin Meek, Peter Lurie, G. Caleb Alexander

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018

Upload

Hemalkumar B. Mehta, Thomas J. Moore

, G. Caleb Alexander

Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin

Download from doi.org

Thomas J. Moore

, James Heyward, Gerard Anderson, G. Caleb Alexander

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

Download from doi.org

Hemalkumar B. Mehta

, Stephan Ehrhardt, Thomas J. Moore

, Jodi B. Segal, G. Caleb Alexander

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Download from doi.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Sonal Singh, Thomas J. Moore

Efficacy and Safety of Hydroxychloroquine and Chloroquine for COVID-19: A systematic review

Upload

Thomas J. Moore

, Richard L. Morrow, Colin R. Dormuth, Barbara Mintzes

US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)

Upload

2019 Yao Qiao, G. Caleb Alexander, Thomas J. Moore

Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016

Upload

2018 Thomas J. Moore

, Hanzhe Zhang, Gerard Anderson, G. Caleb Alexander

Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016

Upload

Thomas J. Moore

, Donald R. Mattison

Assessment of Patterns of Potentially Unsafe Use of Zolpidem

Upload

2017 Steven Woloshin, Lisa M. Schwartz, Brian White, Thomas J. Moore

The Fate of FDA Postapproval Studies

Upload

Thomas J. Moore

, Donald R. Mattison

Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race

Upload

2016 Thomas J. Moore

, Curt D. Furberg

The Harms of Antipsychotic Drugs: Evidence from Key Studies

Upload

Thomas J. Moore

, Curt D. Furberg, Donald R. Mattison, Michael R. Cohen

Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014

Upload

2015 Thomas J. Moore

, Curt D. Furberg

Electronic Health Data for Postmarket Surveillance: A Vision Not Realized

Download from link.springer.com

2014 Thomas J. Moore

, Michael R. Cohen, Donald R. Mattison

Dabigatran, bleeding, and the regulators

Download from dx.doi.org

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Thomas J. Moore